- Home
- ALDX vs IMAB Comparison
ALDX vs IMAB Comparison
Compare ALDX & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALDX
- IMAB
- Stock Information
- Founded
- ALDX 2004
- IMAB 2014
- Country
- ALDX United States
- IMAB United States
- Employees
- ALDX N/A
- IMAB N/A
- Industry
- ALDX Biotechnology: Pharmaceutical Preparations
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- ALDX Health Care
- IMAB Health Care
- Exchange
- ALDX Nasdaq
- IMAB Nasdaq
- Market Cap
- ALDX 342.3M
- IMAB 384.6M
- IPO Year
- ALDX 2014
- IMAB 2020
- Fundamental
- Price
- ALDX $5.39
- IMAB $4.09
- Analyst Decision
- ALDX Strong Buy
- IMAB Strong Buy
- Analyst Count
- ALDX 2
- IMAB 5
- Target Price
- ALDX $9.50
- IMAB $6.80
- AVG Volume (30 Days)
- ALDX 772.4K
- IMAB 2.0M
- Earning Date
- ALDX 11-06-2025
- IMAB 11-02-2025
- Dividend Yield
- ALDX N/A
- IMAB N/A
- EPS Growth
- ALDX N/A
- IMAB N/A
- EPS
- ALDX N/A
- IMAB N/A
- Revenue
- ALDX N/A
- IMAB N/A
- Revenue This Year
- ALDX N/A
- IMAB N/A
- Revenue Next Year
- ALDX $43.00
- IMAB N/A
- P/E Ratio
- ALDX N/A
- IMAB N/A
- Revenue Growth
- ALDX N/A
- IMAB N/A
- 52 Week Low
- ALDX $1.14
- IMAB $0.60
- 52 Week High
- ALDX $7.20
- IMAB $5.90
- Technical
- Relative Strength Index (RSI)
- ALDX 45.98
- IMAB 50.05
- Support Level
- ALDX $5.48
- IMAB $3.20
- Resistance Level
- ALDX $5.88
- IMAB $4.64
- Average True Range (ATR)
- ALDX 0.27
- IMAB 0.45
- MACD
- ALDX -0.07
- IMAB -0.14
- Stochastic Oscillator
- ALDX 1.87
- IMAB 40.27
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).